ArticlemAbs
Reproducibility and flexibility of monoclonal antibody production with
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Beyond Starch: Towards a Scalable Potato Platform for Molecular Farming.Plant biotechnology journal · 2026Review
- Posttranslational modifications of heterologous proteins expressed in Nicotiana benthamiana.Plant biotechnology journal · 2026Review
- Protein engineering strategies to optimise recombinant product synthesis and accumulation in Nicotiana benthamiana.Plant biotechnology journal · 2026Review
- Developing downstream processes for the purification of recombinant proteins and small molecules from Nicotiana benthamiana biomass.Plant biotechnology journal · 2026Review
- Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Monoclonal antibodies in veterinary antiviral immunotherapy: technologies, applications and challenges.Veterinary research communications · 2025Review
- Article
- Production of Plant Virus-Derived Hybrid Nanoparticles Decorated with Different Nanobodies.ACS nano · 2024Article
- Article
- Efficient Expression of Functionally Active Aflibercept with Designed N-glycans.Antibodies (Basel, Switzerland) · 2024Article
- Plant virus-derived nanoparticles decorated with genetically encoded SARS-CoV-2 nanobodies display enhanced neutralizing activity.Plant biotechnology journal · 2024Article
- Platform-Specific FcAntibodies (Basel, Switzerland) · 2024Article
- Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium.Frontiers in immunology · 2024Article
- Plant-based biopharmaceutical engineering.Nature reviews bioengineering · 2023Review
- Feasibility of plant-expression system for production of recombinant anti-human IgE: An alternative production platform for therapeutic monoclonal antibodies.Frontiers in plant science · 2022Article
- Comparative analysis of plant transient expression vectors for targeted N-glycosylation.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
The ongoing SARS-CoV-2 coronavirus pandemic of 2020-2021 underscores the need for manufacturing platforms that can rapidly produce monoclonal antibody (mAb) therapies. As reported here, a platform based on
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.